68Ga-PSMA-11 PET视觉不可见前列腺内肿瘤病灶的患病率、特征及基于影像组学特征的检测
本研究基于前瞻性训练队列(n=20)和外部验证队列(n=52)的原发性前列腺癌患者,量化视觉PSMA-PET判读遗漏的前列腺内病灶并评估影像组学特征(RFs)的检测能力。训练队列中60%患者存在视觉遗漏病灶,中位直径2.2 mm,75%为临床显著癌;两个RFs在训练队列ROC-AUC≥0.93,验证队列灵敏度≥0.8。视觉判读可能遗漏小而临床显著的病灶,RFs有助于发现这些病灶。
要点
- 视觉PSMA-PET判读可遗漏小但临床显著的前列腺内病灶。
- 两个LBP相关RFs在训练队列ROC-AUC≥0.93,验证队列灵敏度≥0.8。
- 遗漏病灶中位直径2.2 mm,多数为ISUP>1的临床显著癌。
核心结论
- 视觉PSMA-PET判读可能遗漏小而临床显著的前列腺癌,影像组学特征可辅助检测这些病灶。
研究设计与样本
- 研究包含前瞻性训练队列(n=20)和外部验证队列(n=52)的原发性前列腺癌患者,所有患者接受68Ga-PSMA-11 PET/CT及术后组织学切片。
主要发现
- 训练队列中视觉PET判读遗漏134个肿瘤病灶,60%(12/20)患者存在遗漏,其中75%为临床显著癌(ISUP>1)。
- 遗漏病灶中位直径2.2 mm(范围1-6 mm),NCCN风险分组在有无视觉遗漏病灶患者间分布均衡(p<0.05)。
- 两个RFs(LBP size-zone non-uniformality normalized和LBP small-area emphasis)在视觉未知前列腺癌检测中表现优异(Mann-Whitney U: p<0.01,ROC-AUC≥0.93)。
- 验证队列中50%(26/52)患者存在遗漏,其中77%为临床显著癌,两个RFs灵敏度均≥0.8。
关键数值与推荐
- 训练队列遗漏病灶中位直径2.2 mm(范围1-6 mm),75%为ISUP>1。
- 两个RFs训练队列ROC-AUC≥0.93(Mann-Whitney U: p<0.01),验证队列灵敏度≥0.8。
- 验证队列遗漏患者中77%为临床显著癌。
临床怎么用
- 对于视觉PSMA-PET判读阴性但临床怀疑的前列腺癌患者,可考虑结合影像组学特征辅助检测视觉不可见病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary prostate cancer (PCa) can be visualized on prostate-specific membrane antigen positron emission tomography (PSMA-PET) with high accuracy. However, intraprostatic lesions may be missed by visual PSMA-PET interpretation. In this work, we quantified and characterized the intraprostatic lesions which have been missed by visual PSMA-PET image interpretation. In addition, we investigated whether PSMA-PET-derived radiomics features (RFs) could detect these lesions. METHODOLOGY: This study consists of two cohorts of primary PCa patients: a prospective training cohort (n = 20) and an external validation cohort (n = 52). All patients underwent 68Ga-PSMA-11 PET/CT and histology sections were obtained after surgery. PCa lesions missed by visual PET image interpretation were counted and their International Society of Urological Pathology score (ISUP) was obtained. Finally, 154 RFs were derived from the PET images and the discriminative power to differentiate between prostates with or without visually undetectable lesions was assessed and areas under the receiver-operating curve (ROC-AUC) as well as sensitivities/specificities were calculated. RESULTS: In the training cohort, visual PET image interpretation missed 134 tumor lesions in 60% (12/20) of the patients, and of these patients, 75% had clinically significant (ISUP > 1) PCa. The median diameter of the missed lesions was 2.2 mm (range: 1-6). Standard clinical parameters like the NCCN risk group were equally distributed between patients with and without visually missed lesions (p < 0.05). Two RFs (local binary pattern (LBP) size-zone non-uniformality normalized and LBP small-area emphasis) were found to perform excellently in visually unknown PCa detection (Mann-Whitney U: p < 0.01, ROC-AUC: ≥ 0.93). In the validation cohort, PCa was missed in 50% (26/52) of the patients and 77% of these patients possessed clinically significant PCa. The sensitivities of both RFs in the validation cohort were ≥ 0.8. CONCLUSION: Visual PSMA-PET image interpretation may miss small but clinically significant PCa in a relevant number of patients and RFs can be implemented to uncover them. This could be used for guiding personalized treatments.
引用
- Zamboglou C, Bettermann AS, Gratzke C, et al. Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 33210239. doi:10.1007/s00259-020-05111-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。